Understanding Biomarker Differences Becomes Critical as Precision Medicine Rises in Melanoma

Source: OncLive, December 2020

With the identification of actionable alterations, precision medicine continues to lead the way in all areas of oncology, but especially in melanoma, according to Jason J. Luke, MD, FACP, who added that, in order to successfully apply personalized therapy, it’s critical to be fluent in the differences between biomarkers.

“Precision medicine, especially in the field of oncology, defines the way we develop new drugs and how we select therapies for individual patients.

When we think of actionable alterations, we commonly think of something such as an NTRK fusion.

READ THE ORIGINAL FULL ARTICLE